Schizophrenia: Treatment targets beyond monoamine systems

Annual Review of Pharmacology and Toxicology

Volumn 51, Issue , 2011, Pages 189-209

  Ibrahim, Hisham M ^a,b   Tamminga, Carol A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

acetylcholine; cognition; component symptom complexes; glutamate; psychosis

Indexed keywords

3 AMINOPROPYL(DIETHOXYMETHYL)PHOSPHINIC ACID; 3 PHENYLSULFONYL 8 (1 PIPERAZINYL)QUINOLINE; 4 [2 AMINO 4 (METHYLTHIO)BUTYRYLAMINO] 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ASENAPINE; ATOMOXETINE; CHLORPROMAZINE; CLOZAPINE; CYCLOSERINE; DAR 0100; DIHYDREXIDINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; ILOPERIDONE; MOOD STABILIZER; NEUROLEPTIC AGENT; NORCLOZAPINE; OLANZAPINE; PERPHENAZINE; PHYSOSTIGMINE; PLACEBO; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARENICLINE; XANOMELINE; ZIPRASIDONE;

AKATHISIA; ANHEDONIA; ANTISOCIAL BEHAVIOR; ARTICLE; ATTENTION DISTURBANCE; COGNITION; COGNITIVE DEFECT; DELUSION; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG TREATMENT FAILURE; DYSKINESIA; DYSTONIA; EXPERIMENTAL MODEL; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; HUMAN; MEMORY DISORDER; MENTAL INSTABILITY; METABOLIC SYNDROME X; MONOAMINERGIC SYSTEM; NAUSEA AND VOMITING; NEGATIVE SYNDROME; NONHUMAN; PARKINSONISM; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; TEMPORAL LOBE; THOUGHT DISORDER; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

ANIMALIA;

EID: 79951988420     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.010909.105851     Document Type: Article

References (170)

1. Tamminga CA, Holcomb HH. 2004. Phenotype of schizophrenia: a review and formulation. Mol. Psychiatry 10:27-39 (Pubitemid 40139587)
2. Carpenter WT Jr, Buchanan RW. 1994. Schizophrenia. N. Engl. J. Med. 330:681-90 (Pubitemid 24066986)
3. Sartorius N, Shapiro R, Jablensky A. 1974. The International Pilot Study of Schizophrenia. Schizophr. Bull. 1:21-34
4. Davis R, Whittington R, Bryson HM. 1997. Nefazodone: a review of its pharmacology and clinical efficacy in the management of major depression. Drugs 53:608-36 (Pubitemid 27145956)
5. Awad AG, Voruganti LN. 2008. The burden of schizophrenia on caregivers: a review. Pharmacoeconomics 26:149-62
6. Tamminga CA, Davis JM. 2007. The neuropharmacology of psychosis. Schizophr. Bull. 33:937-46 (Pubitemid 47216663)
7. Davis JM. 1969. Review of antipsychotic drug literature. In Diagnosis and Drug Treatment of Psychiatric Disorders, ed. DF Klein, JM Davis, pp. 52-138. Baltimore, MD: The Williams and Wilkins Company
8. Hyman SE, Fenton WS. 2003. Medicine: What are the right targets for psychopharmacology? Science 299:350-51 (Pubitemid 36120025)
9. Freedman R. 2003. Schizophrenia. N. Engl. J. Med. 349:1738-49 (Pubitemid 37315012)
10. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. 1999. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr. Res. 35:51-68 (Pubitemid 29023554)
11. Leucht S, Kissling W, Davis JM. 2009. Second-generation antipsychotics for schizophrenia: Can we resolve the conflict? Psychol. Med. 39:1591-602
12. Leucht S, Wahlbeck K, Hamann J, Kissling W. 2003. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361:1581-89; comment 362:404, author reply 404-5 (Pubitemid 36578993)
13. Marder SR. 2006. The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia. Dialogues Clin. Neurosci. 8:109-13
14. Geyer MA, Tamminga C. 2004. MATRICS: Measurement and Treatment Research to Improve Cognition in Schizophrenia. Psychopharmacology 174:1-162
15. Green MF, Olivier B, Crawley JN, Penn DL, Silverstein S. 2005. Social cognition in schizophrenia: recommendations from the Measurement and Treatment Research to Improve Cognition in Schizophrenia New Approaches Conference. Schizophr. Bull. 31:882-887 (Pubitemid 41437782)
16. Zink M, Englisch S, Meyer-Lindenberg A. 2010. Polypharmacy in schizophrenia. Curr. Opin. Psychiatry 23:103-11
17. American Psychiatric Association. 2000. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision (DSM-IV-TR). Washington, DC: Am. Psychiatr. Assoc.
18. Tamminga CA. 1994. Development in somatic treatments: introduction. Am. J. Psychiatry 151:216-19
19. Saks ER. 2007. The Center Cannot Hold: My Journey Through Madness. New York: Hyperion
20. Nasar S. 1998. A Beautiful Mind: A Biography of John Forbes Nash, Jr., Winner of the Nobel Prize in Economics, 1994. New York: Simon & Schuster
21. Harvey PD, Howanitz E, Parrella M, White L, Davidson M, et al. 1998. Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am. J. Psychiatry 155:1080-86 (Pubitemid 28357734)
22. Breier A, Schreiber JL, Dyer J, Pickar D. 1991. National Institute of Mental Health longitudinal study of chronic schizophrenia: prognosis and predictors of outcome. Arch. Gen. Psychiatry 48:239-46
23. Ho BC, Nopoulos P, Flaum M, Arndt S, Andreasen NC. 1998. Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life. Am. J. Psychiatry 155:1196-201 (Pubitemid 28402512)
24. Flashman LA, Green MF. 2004. Review of cognition and brain structure in schizophrenia: profiles, longitudinal course, and effects of treatment. Psychiatr. Clin. North Am. 27:1-18, vii (Pubitemid 38367767)
25. Cornblatt BA, Erlenmeyer-Kimling L. 1985. Global attentional deviance as a marker of risk for schizophrenia: specificity and predictive validity. J. Abnorm. Psychol. 94:470-86 (Pubitemid 16159635)
26. Bilder RM, Lipschutz-Broch L, Reiter G, Geisler S, Mayerhoff D, Lieberman JA. 1991. Neuropsycho-logical deficits in the early course of first episode schizophrenia. Schizophr. Res. 5:198-99
27. Gur RE, Turetsky BI, Bilker WB, Gur RC. 1999. Reduced gray matter volume in schizophrenia. Arch. Gen. Psychiatry 56:905-11 (Pubitemid 29480126)
28. Gur RE, Maany V, Mozley PD, Swanson C, Bilker W, Gur RC. 1998. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am. J. Psychiatry 155:1711-17 (Pubitemid 28547495)
29. Hill SK, Beers SR, Kmiec JA, Keshavan MS, Sweeney JA. 2004. Impairment of verbal memory and learning in antipsychotic-naive patients with first-episode schizophrenia. Schizophr. Res. 68:127-36 (Pubitemid 38526137)
30. Saykin AJ, Shtasel DL, Gur RE, Kester DB, Mozley LH, et al. 1994. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch. Gen. Psychiatry 51:124-31
31. Brickman AM, Buchsbaum MS, Bloom R, Bokhoven P, Paul-Odouard R, et al. 2004. Neuropsychological functioning in first-break, never-medicated adolescents with psychosis. J. Nerv. Men. Dis. 192:615-22 (Pubitemid 39238409)
32. Kravariti E, Morris RG, Rabe-Hesketh S, Murray RM, Frangou S. 2003. The Maudsley Early-Onset Schizophrenia Study: cognitive function in adolescent-onset schizophrenia. Schizophr. Res. 65:95-103 (Pubitemid 37434016)
33. Hoff AL, Svetina C, Maurizio AM, Crow TJ, Spokes K, DeLisi LE. 2005. Familial cognitive deficits in schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 133B:43-49 (Pubitemid 40175613)
34. Myles-Worsley M, Park S. 2002. Spatial working memory deficits in schizophrenia patients and their first degree relatives from Palau, Micronesia. Am. J. Med. Genet. Neuropsychiatr. Genet. 114:609-15
35. Niendam TA, Bearden CE, Rosso IM, Sanchez LE, Hadley T, et al. 2003. A prospective study of childhood neurocognitive functioning in schizophrenic patients and their siblings. Am. J. Psychiatry 160:2060-62 (Pubitemid 39619649)
36. Brewer WJ, Francey SM, Wood SJ, Jackson HJ, Pantelis C, et al. 2005. Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. Am. J. Psychiatry 162:71-78 (Pubitemid 40095675)
37. Censits DM, Ragland JD, Gur RC, Gur RE. 1997. Neuropsychological evidence supporting a neurode-velopmental model of schizophrenia: a longitudinal study. Schizophr. Res. 24:289-98 (Pubitemid 27163240)
38. Goldberg TE, Weinberger DR. 1996. Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies. J. Clin. Psychiatry 57:62-65 (Pubitemid 26327760)
39. Braff DL. 1993. Information processing and attention dysfunctions in schizophrenia. Schizophr. Bull. 19:233-59 (Pubitemid 23183147)
40. D'Esposito M. 1998. Serotonin neurotoxicity: implications for cognitive neuroscience and neurology. Neurology 51:1529-30 (Pubitemid 28565226)
41. Dickinson D, Iannone VN, Wilk CM, Gold JM. 2004. General and specific cognitive deficits in schizophrenia. Biol. Psychiatry 55:826-33 (Pubitemid 38429874)
42. Gur RC, Ragland JD, Moberg PJ, Bilker WB, Kohler C, et al. 2001. Computerized neurocognitive scanning: II. The profile of schizophrenia. Neuropsychopharmacology 25:777-88 (Pubitemid 32995960)
43. Heinrichs RW, Zakzanis KK. 1998. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12:426-45 (Pubitemid 28323862)
44. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. 2004. Identification of separable cognitive factors in schizophrenia. Schizophr. Res. 72:29-39 (Pubitemid 39452903)
45. Elvevag B, Brown GDA, McCormack T, Vousden JI, Goldberg TE. 2004. Identification of tone duration, line length, and letter position: an experimental approach to timing and working memory deficits in schizophrenia. J. Abnorm. Psychol. 113:509-21 (Pubitemid 39431106)
46. Cannon TD, Huttunen MO, Lonnqvist J, Tuulio-Henriksson A, Pirkola T, et al. 2000. The inheritance of neuropsychological dysfunction in twins discordant for schizophrenia. Am. J. Hum. Genet. 67:369-82 (Pubitemid 30616742)
47. 108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl. Acad. Sci. USA 98:6917-22 (Pubitemid 32538317)
48. Green MF, Kern RS, Braff DL, Mintz J. 2000. Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the "right stuff "? Schizophr. Bull. 26:119-36 (Pubitemid 30317696)
49. Saykin AJ, Gur RC, Gur RE, Mozley PD, Mozley LH, et al. 1991. Neuropsychological function in schizophrenia: selective impairment in memory and learning. Arch. Gen. Psychiatry 48:618-24
50. Andreasen N, Paradiso S,O'Leary D. 1998. "Cognitive dysmetria"as anintegrative theoryofschizophre-nia: a dysfunction in cortical-subcortical-cerebellar circuitry? Schizophr. Bull. 24:203-18
51. Cohen RA, Kaplan RF, Zuffante P, Moser DJ, Jenkins MA, et al. 1999. Alteration of intention and self-initiated action associated with bilateral anterior cingulotomy.J. Neuropsychiatry Clin. Neurosci.11:444-53
52. Goldman-Rakic PS. 1994. Working memory dysfunction in schizophrenia. J. Neuropsychiatry Clin. Neurosci. 6:348-57 (Pubitemid 24344855)
53. Green MF. 1996. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry 153:321-30 (Pubitemid 26074706)
54. Green MF. 1998. Schizophrenia fromaNeurocognitive Perspective: Probing the Impenetrable Darkness. Boston: Allyn and Bacon
55. Tamminga CA. 2008. Principles of the pharmacotherapy of schizophrenia. In Neurobiology of Mental Illness, ed. DS Charney, EJ Nestler, pp. 329-47. New York: Oxford Univ. Press. 3rd ed.
56. Coward DM. 1992. General pharmacology of clozapine. Br. J. Psychiatry Suppl. 17:5-11
57. Davis JM, Chen N, Glick ID. 2003. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry 60:553-64; comment 63:935-37, author reply 937-39 (Pubitemid 36682312)
58. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, et al. 2005. Effectiveness of antipsy-chotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353:1209-23 (Pubitemid 41345943)
59. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, et al. 2003. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am. J. Psychiatry 160:1396-404 (Pubitemid 41070913)
60. 2 receptors. Prog. Neuropsychopharmacol. Biol. Psychiatry 27:1081-90 (Pubitemid 37464954)
61. Tamminga CA, Carlsson A. 2002. Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr. Drug Targets CNS Neurol. Disord. 1:141-47
62. Conley RR, Kelly DL. 2001. Management of treatment resistance in schizophrenia. Biol. Psychiatry 50:898-911 (Pubitemid 34020701)
63. Tamminga CA. 2002. Partial dopamine agonists in the treatment of psychosis. J. Neural Transm. 109:411-20 (Pubitemid 34251643)
64. Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dube S, et al. 2008. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am. J. Psychiatry 165:1033-39
65. Janowsky DS, El-Yousef MK, Davis JM. 1974. Acetylcholine and depression. Psychosom. Med. 36:248-57
66. Janowsky DS, Davis JM. 2009. Antipsychotic properties of muscarinic drugs. Am. J. Psychiatry 166:110-11
67. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, et al. 2007. Corrigenda: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med. 13:1264 (Pubitemid 47530624)
68. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, et al. 2007. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med. 13:1102-7 (Pubitemid 47517511)
69. Alexander GE, Crutcher MD, DeLong MR. 1990. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog. Brain Res. 85:119-46
70. DeLong MR. 1990. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 13:281-85
71. Green MF. 1996. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry 153:321-30 (Pubitemid 26074706)
72. Nuechterlein KH, Robbins TW, Einat H. 2005. Distinguishing separable domains of cognition in human and animal studies: What separations are optimal for targeting interventions? A summary of recommendations from breakout group 2 at the Measurement and Treatment Research to Improve Cognition in Schizophrenia New Approaches Conference. Schizophr. Bull. 31:870-74 (Pubitemid 41437780)
73. Martin LF, Kem WR, Freedman R. 2004. α7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology 174:54-64 (Pubitemid 38925091)
74. Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, et al. 2006. Proof-of-concept trial of an α7 nicotinic agonist in schizophrenia. Arch. Gen. Psychiatry 63:630-38 (Pubitemid 43848294)
75. Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, et al. 2008. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am. J. Psychiatry 165:1040-47
76. Hyde TM, Crook JM. 2001. Cholinergic systems and schizophrenia: primary pathology or epiphenom-ena? J. Chem. Neuroanat. 22:53-63 (Pubitemid 32695509)
77. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. 2000. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Soc. Biol. Psychiatry 48:381-88
78. Friedman JI. 2004. Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology 174:45-53 (Pubitemid 38925090)
79. Mancama D, Arranz MJ, Landau S, Kerwin R. 2003. Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 119B:2-6 (Pubitemid 37064044)
80. Davies MA, Compton-Toth BA, Hufeisen SJ, Meltzer HY, Roth BL. 2005. The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: Is M1 agonism a prerequisite for mimicking clozapine's actions? Psychopharmacology 178:451-60 (Pubitemid 40486985)
81. Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dubé S, et al. 2008. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am. J. Psychiatry 165:1033-39
82. 3 partial agonist. J. Pharmacol. Exp. Ther. 315:1278-87 (Pubitemid 41635416)
83. Weiner DM, Meltzer HY, Veinbergs I, Donohue EM, Spalding TA, et al. 2004. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology 177:207-16 (Pubitemid 40109932)
84. Tamminga CA, Ibrahim HM, Eamma J, Corritorri S, Nichols A, et al. 2006. ACP104 initial phase II results: putative antipsychotic drug and cognition enhancer. Presented at Ann. Meet. Am. Coll. Neuropsy-chopharmacol., 45th, Hollywood, Fla.
85. 1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology 174:3-16 (Pubitemid 38925085)
86. Akil M, Kolachana BS, Rothmond DA, Hyde TM, Weinberger DR, Kleinman JE. 2003. Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J. Neurosci. 23:2008-13 (Pubitemid 36368887)
87. 1 dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am. J. Psychiatry 159:761-67 (Pubitemid 34465049)
88. 1 receptors in schizophrenia revealed by PET. Nature 385:634-36
89. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, et al. 2003. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone versus placebo in patients with schizophrenia and schizoaf-fective disorder. Arch. Gen. Psychiatry 60:681-90 (Pubitemid 36818630)
90. Selemon LD, Rajkowska G, Goldman-Rakic PS. 1995. Abnormally high neuronal density in the schizophrenic cortex: a morphometric analysis of prefrontal area 9 and occipital area 17. Arch. Gen. Psychiatry 52:805-18
91. 1 agonist, is safe and tolerated in patients with schizophrenia. Schizophr. Res. 93:42-50 (Pubitemid 46817947)
92. 1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia. Schizophr. Res. 94:332-41 (Pubitemid 47039290)
93. Kelly DL, Buchanan RW, Boggs DL, McMahon RP, Dickinson D, et al. 2009. A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. J. Clin. Psychiatry 70:518-25
94. Friedman JI, Carpenter D, Lu J, Fan J, Tang CY, et al. 2008. A pilot study of adjunctive atomoxe-tine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia. J. Clin. Psychopharmacol. 28:59-63
95. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA. 2001. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25:455-67 (Pubitemid 32830950)
96. Tamminga C. 1999. Glutamatergic aspects of schizophrenia. Br. J. Psychiatry Suppl. 37:12-15 (Pubitemid 29089304)
97. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, et al. 1994. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51:199-214 (Pubitemid 24081509)
98. Tsai G, Passani LA, Slusher BS, Carter R, Baer L, et al. 1995. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch. Gen. Psychiatry 52:829-36
99. Gao XM, Sakai K, Roberts RC, Conley RR, Dean B, Tamminga CA. 2000. Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am. J. Psychiatry 157:1141-49 (Pubitemid 30432497)
100. Tsai GE, Lin PY. 2009. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmis-sion in schizophrenia, a critical review and meta-analysis. Curr. Pharm. Des. 16:522-37
101. F. Hoffmann-La Roche Ltd. 2010. Central nervous system: two potential breakthrough medicines in late-stage development. http://www.roche.com/ investors/ir-update/inv-update-2010-03-18.htm
102. Schlumberger C, Schafer D, Barberi C, More L, Nagel J, et al. 2009. Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition. Behav. Pharmacol. 20:56-66
103. Lewis DA, Cho RY, Carter CS, Eklund K, Forster S, et al. 2008. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am. J. Psychiatry 165:1585-93
104. Geyer MA, Markou A. 1995. Animal models of psychiatric disorders. In Psychopharmacology: The Fourth Generation of Progress, ed. FE Bloom, DJ Kupfer, pp. 787-97. New York: Raven
105. Tamminga CA, Stan AD, Wagner AD. 2010. The hippocampal formation in schizophrenia. Am. J. Psychiatry 167:1178-93
106. Egan MF, Duncan CC, Suddath RL, Kirch DG, Mirsky AF, Wyatt RJ. 1994. Event-related potential abnormalities correlate with structural brain alterations and clinical features in patients with chronic schizophrenia. Schizophr. Res. 11:259-71 (Pubitemid 24063746)
107. Szeszko PR, Strous RD, Goldman RS, Ashtari M, Knuth KH, et al. 2002. Neuropsychological correlates of hippocampal volumes in patients experiencing a first episode of schizophrenia. Am. J. Psychiatry 159:217-26 (Pubitemid 34126898)
108. Owen MJ, Craddock N, Jablensky A. 2007. The genetic deconstruction of psychosis. Schizophr. Bull. 33:905-11 (Pubitemid 47216654)
109. Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, et al. 2009. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 460:753-57
110. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, et al. 2009. Common variants conferring risk of schizophrenia. Nature 460:744-47
111. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, et al. 2009. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460:748-52
112. Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, et al. 2008. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 320:539-43 (Pubitemid 351590668)
113. Fanous AH, Kendler KS. 2008. Genetics of clinical features and subtypes of schizophrenia: a review of the recent literature. Curr. Psychiatry Rep. 10:164-70
114. Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, et al. 2008. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 31:234-42
115. Lewis DA, Moghaddam B. 2006. Cognitive dysfunction inschizophrenia: convergence ofγ-aminobutyric acid and glutamate alterations. Arch. Neurol. 63:1372-76 (Pubitemid 44547546)
116. Carlsson A, Carlsson ML. 2006. A dopaminergic deficit hypothesis of schizophrenia: the path to discovery. Dialogues Clin. Neurosci. 8:137-42
117. Harrison PJ, West VA. 2006. Six degrees of separation: on the prior probability that schizophrenia susceptibility genes converge on synapses, glutamate and NMDA receptors. Mol. Psychiatry 11:981-83 (Pubitemid 44631640)
118. Porter RH, Eastwood SL, Harrison PJ. 1997. Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex, and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia. Brain Res. 751:217-31 (Pubitemid 27132551)
119. Law AJ, Deakin JF. 2001. Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. NeuroReport 12:2971-74 (Pubitemid 32882018)
120. Eastwood SL, McDonald B, Burnet PWJ, Beckwith JP, Kerwin RW, Harrison PJ. 1995. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Mol. Brain Res. 29:211-23
121. Kolomeets NS, Orlovskaya DD, Uranova NA. 2007. Decreased numerical density of CA3 hippocampal mossy fiber synapses in schizophrenia. Synapse 61:615-21 (Pubitemid 46934008)
122. Reif A, Fritzen S, Finger M, Strobel A, Lauer M, et al. 2006. Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Mol. Psychiatry 11:514-22
123. Lauer M, Beckmann H, Senitz D. 2003. Increased frequency of dentate granule cells with basal dendrites in the hippocampal formation of schizophrenics. Psychiatry Res. 122:89-97 (Pubitemid 36506476)
124. Javitt DC, Zukin SR. 1991. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148:1301-8
125. Tamminga CA. 1998. Schizophrenia and glutamatergic transmission. Crit. Rev. Neurobiol. 12:21-36 (Pubitemid 28177262)
126. Coyle JT. 2006. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell. Mol. Neurobiol. 26:365-84
127. Levy R, Goldman-Rakic PS. 1999. Association of storage and processing functions in the dorsolateral prefrontal cortex of the nonhuman primate. J. Neurosci. 19:5149-58 (Pubitemid 29270150)
128. Goldberg TE, Gold JM. 1995. Neurocognitive deficits in schizophrenia. In Schizophrenia, ed. SR Hirsch, DR Weinberger, pp. 142-62. Oxford, UK: Blackwell Sci. Ltd.
129. Gold JM. 2004. Cognitive deficits as treatment targets in schizophrenia. Schizophr. Res. 72:21-28 (Pubitemid 39452902)
130. Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, et al. 1995. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch. Gen. Psychiatry 52:258-66
131. Lewis DA, Cruz DA, Melchitzky DS, Pierri JN. 2001. Lamina-specific deficits in parvalbumin-immunoreactive varicosities in the prefrontal cortex of subjects with schizophrenia: evidence for fewer projections from the thalamus. Am. J. Psychiatry 158:1411-22 (Pubitemid 32847239)
132. Benes FM, Berretta S. 2001. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 25:1-27 (Pubitemid 32493819)
133. Guidotti A, Auta J, Davis JM, Dong E, Grayson DR, et al. 2005. GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacology 180:191-205 (Pubitemid 40909664)
134. Rudolph U, Mohler H. 2006. GABA-based therapeutic approaches: GABAA receptor subtype functions. Curr. Opin. Pharmacol. 6:18-23 (Pubitemid 43103815)
135. Gottesman II, McGuffin P, Farmer AE. 1987. Clinical genetics as clues to the "real" genetics of schizophrenia (a decade of modest gains while playing for time). Schizophr. Bull. 13:23-47 (Pubitemid 18037636)
136. McGuffin P,Farmer A, Gottesman II. 1987. Is there really a split in schizophrenia? The genetic evidence. Br. J. Psychiatry 150:581-92 (Pubitemid 17061219)
137. McGuffin P, Gottesman II, Swerdlow RH, Binder D, Parker WD, et al. 1999. Risk factors for schizophrenia. N. Engl. J. Med. 341:370-72
138. Gould TD, Gottesman II. 2006. Psychiatric endophenotypes and the development of valid animal models. Genes Brain Behav. 5:113-19 (Pubitemid 43344963)
139. Gottesman II, Gould T. 2003. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 160:636-45 (Pubitemid 41079594)
140. Braff DL, Light GA. 2005. The use of neurophysiological endophenotypes to understand the genetic basis of schizophrenia. Dialogues Clin. Neurosci. 7:125-35 (Pubitemid 40961532)
141. Braff DL, Freedman R, Schork NJ, Gottesman II. 2007. Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. Schizophr. Bull. 33:21-32 (Pubitemid 46026257)
142. Thaker GK. 2007. Endophenotypic studies in schizophrenia: promise and challenges. Schizophr. Bull. 33:1-2 (Pubitemid 46026252)
143. Ivleva EI, Morris DW, Moates AF, Suppes T, Thaker GK, Tamminga CA. 2010. Genetics and intermediate phenotypes of the schizophrenia-bipolar disorder boundary. Neurosci. Biobehav. Rev. 34:897-921
144. Kaymaz N, van Os J. 2010. Extended psychosis phenotype-yes: single continuum-unlikely. Psychol. Med. 18:1-4
145. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, et al. 2002. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 71:877-92 (Pubitemid 135750519)
146. Miyakawa T, Leiter LM, Gerber DJ, Gainetdinov RR, Sotnikova TD,et al. 2003. Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc. Natl. Acad. Sci. USA 100:8987-92 (Pubitemid 36899210)
147. Ishizuka K, Paek M, Kamiya A, Sawa A. 2006. A review of Disrupted-In-Schizophrenia-1 (DISC1): neurodevelopment, cognition, and mental conditions. Biol. Psychiatry 59:1189-97
148. Porteous DJ, Thomson P, Brandon NJ, Millar JK. 2006. The genetics and biology of DISC1-an emerging role in psychosis and cognition. Biol. Psychiatry 60:123-31
149. Millar JK, Christie S, Anderson S, Lawson D, Hsiao-Wei LD, et al. 2001. Genomic structure and localisation within a linkage hotspot of Disrupted In Schizophrenia 1, a gene disrupted by a translocation segregating with schizophrenia. Mol. Psychiatry 6:173-78 (Pubitemid 32187867)
150. Ekelund J, Hennah W, Hiekkalinna T, Parker A, Meyer J, et al. 2004. Replication of 1q42 linkage in Finnish schizophrenia pedigrees. Mol. Psychiatry 9:1037-41 (Pubitemid 39524292)
151. Hodgkinson CA, Goldman D, Jaeger J, Persaud S, Kane JM, et al. 2004. Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. Am. J. Hum. Genet. 75:862-72 (Pubitemid 39390493)
152. Macgregor S, Visscher PM, Knott SA, Thomson P, Porteous DJ, et al. 2004. A genome scan and follow-up study identify a bipolar disorder susceptibility locus on chromosome 1q42. Mol. Psychiatry 9:1083-90 (Pubitemid 40065453)
153. Hamshere ML, Bennett P, Williams N, Segurado R, Cardno A, et al. 2005. Genomewide linkage scan in schizoaffective disorder: significant evidence for linkage at 1q42 close to DISC1, and suggestive evidence at 22q11 and 19p13. Arch. Gen. Psychiatry 62:1081-88 (Pubitemid 41396933)
154. Thomson PA, Wray NR, Millar JK, Evans KL, Hellard SL, et al. 2005. Association between the TRAX/DISC locus and both bipolar disorder and schizophrenia in the Scottish population. Mol. Psychiatry 10:657-68 (Pubitemid 40961736)
155. Zhang F, Sarginson J, Crombie C, Walker N, St Clair D, Shaw D. 2006. Genetic association between schizophrenia and the DISC1 gene in the Scottish population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141B:155-59 (Pubitemid 43214791)
156. Chen QY, Chen Q, Feng GY, Lindpaintner K, Wang LJ, et al. 2007. Case-control association study of Disrupted-in-Schizophrenia-1 (DISC1) gene and schizophrenia in the Chinese population. J. Psychiatr. Res. 41:428-34 (Pubitemid 46201948)
157. Qu M, Tang F, Yue W, Ruan Y, Lu T, et al. 2007. Positive association of the Disrupted-in-Schizophrenia-1 gene (DISC1) with schizophrenia in the Chinese Han population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B:266-70 (Pubitemid 46646662)
158. Kamiya A, Kubo K, Tomoda T, Takaki M, Youn R, et al. 2005. A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development. Nat. Cell Biol. 7:1167-78
159. Hennah W, Varilo T, Kestila M, Paunio T, Arajarvi R, et al. 2003. Haplotype transmission analysis provides evidence of association for DISC1 to schizophrenia and suggests sex-dependent effects. Hum. Mol. Genet. 12:3151-59 (Pubitemid 37508886)
160. Callicott JH, Straub RE, Pezawas L, Egan MF, Mattay VS, et al. 2005. Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Proc. Natl. Acad. Sci. USA 102:8627-32 (Pubitemid 40862786)
161. Li D, Collier DA, He L. 2006. Meta-analysis shows strong positive association of the neuregulin 1 (NRG1) gene with schizophrenia. Hum. Mol. Genet. 15:1995-2002 (Pubitemid 43983273)
162. Munafo MR, Thiselton DL, Clark TG, Flint J. 2006. Association of the NRG1 gene and schizophrenia: a meta-analysis. Mol. Psychiatry 11:539-46
163. Allen NC, Bagade S, McQueen MB, Ioannidis JP, Kavvoura FK, et al. 2008. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat. Genet. 40:827-34 (Pubitemid 351913655)
164. Mei L, Xiong WC. 2008. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat. Rev. Neurosci. 9:437-52 (Pubitemid 351704944)
165. Barros CS, Calabrese B, Chamero P, Roberts AJ, Korzus E, et al. 2009. Impaired maturation of dendritic spines without disorganization of cortical cell layers in mice lacking NRG1/ErbB signaling in the central nervous system. Proc. Natl. Acad. Sci. USA 106:4507-12
166. Konrad A, Winterer G. 2008. Disturbed structural connectivity in schizophrenia-primary factor in pathology or epiphenomenon? Schizophr. Bull. 34:72-92 (Pubitemid 350262274)
167. Hall J, Whalley HC, Job DE, Baig BJ, McIntosh AM, et al. 2006. A neuregulin 1 variant associated with abnormal cortical function and psychotic symptoms. Nat. Neurosci. 9:1477-78 (Pubitemid 44862654)
168. Kircher T, Krug A, Markov V, Whitney C, Krach S, et al. 2009. Genetic variation in the schizophrenia-risk gene neuregulin 1 correlates with brain activation and impaired speech production in a verbal fluency task in healthy individuals. Hum. Brain Mapp. 30:3406-16
169. Chen YJ, Johnson MA, Lieberman MD, Goodchild RE, Schobel S, et al. 2008. Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components. J. Neurosci. 28:6872-83
170. O'Tuathaigh CM, Babovic D, O'Sullivan GJ, Clifford JJ, Tighe O, et al. 2007. Phenotypic characterization of spatial cognition and social behavior in mice with 'knockout' of the schizophrenia risk gene neuregulin 1. Neuroscience 147:18-27 (Pubitemid 46873845)